Logo image of WAY

WAYSTAR HOLDING CORP (WAY) Stock Fundamental Analysis

NASDAQ:WAY - Nasdaq - US9467841055 - Common Stock - Currency: USD

40.44  +0.05 (+0.12%)

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to WAY. WAY was compared to 37 industry peers in the Health Care Technology industry. Both the profitability and the financial health of WAY get a neutral evaluation. Nothing too spectacular is happening here. WAY has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

WAY had negative earnings in the past year.
In the past year WAY had a positive cash flow from operations.
WAY Yearly Net Income VS EBIT VS OCF VS FCFWAY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 50M -50M 100M 150M

1.2 Ratios

WAY has a better Return On Assets (-0.42%) than 83.78% of its industry peers.
WAY has a Return On Equity of -0.62%. This is amongst the best in the industry. WAY outperforms 83.78% of its industry peers.
With an excellent Return On Invested Capital value of 2.21%, WAY belongs to the best of the industry, outperforming 83.78% of the companies in the same industry.
WAY had an Average Return On Invested Capital over the past 3 years of 2.09%. This is significantly below the industry average of 7.17%.
The last Return On Invested Capital (2.21%) for WAY is above the 3 year average (2.09%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -0.42%
ROE -0.62%
ROIC 2.21%
ROA(3y)-0.88%
ROA(5y)N/A
ROE(3y)-1.85%
ROE(5y)N/A
ROIC(3y)2.09%
ROIC(5y)N/A
WAY Yearly ROA, ROE, ROICWAY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 1 -1 2 -2

1.3 Margins

WAY has a Operating Margin of 13.11%. This is amongst the best in the industry. WAY outperforms 94.59% of its industry peers.
In the last couple of years the Operating Margin of WAY has grown nicely.
The Gross Margin of WAY (66.54%) is better than 64.86% of its industry peers.
In the last couple of years the Gross Margin of WAY has declined.
Industry RankSector Rank
OM 13.11%
PM (TTM) N/A
GM 66.54%
OM growth 3Y7.95%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5YN/A
WAY Yearly Profit, Operating, Gross MarginsWAY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 20 40 60

More info and screens

6

2. Health

2.1 Basic Checks

WAY has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
WAY has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, WAY has an improved debt to assets ratio.
WAY Yearly Shares OutstandingWAY Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 50M 100M 150M
WAY Yearly Total Debt VS Total AssetsWAY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

WAY has an Altman-Z score of 3.09. This indicates that WAY is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.09, WAY is in the better half of the industry, outperforming 72.97% of the companies in the same industry.
WAY has a debt to FCF ratio of 8.73. This is a slightly negative value and a sign of low solvency as WAY would need 8.73 years to pay back of all of its debts.
With a Debt to FCF ratio value of 8.73, WAY perfoms like the industry average, outperforming 59.46% of the companies in the same industry.
A Debt/Equity ratio of 0.40 indicates that WAY is not too dependend on debt financing.
WAY has a Debt to Equity ratio of 0.40. This is comparable to the rest of the industry: WAY outperforms 45.95% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF 8.73
Altman-Z 3.09
ROIC/WACC0.21
WACC10.69%
WAY Yearly LT Debt VS Equity VS FCFWAY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 1B 2B 3B

2.3 Liquidity

WAY has a Current Ratio of 2.55. This indicates that WAY is financially healthy and has no problem in meeting its short term obligations.
WAY has a Current ratio of 2.55. This is in the better half of the industry: WAY outperforms 70.27% of its industry peers.
WAY has a Quick Ratio of 2.55. This indicates that WAY is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.55, WAY is in the better half of the industry, outperforming 70.27% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.55
Quick Ratio 2.55
WAY Yearly Current Assets VS Current LiabilitesWAY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 58.57% over the past year.
The Revenue has grown by 19.28% in the past year. This is quite good.
WAY shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.71% yearly.
EPS 1Y (TTM)58.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%227.86%
Revenue 1Y (TTM)19.28%
Revenue growth 3Y17.71%
Revenue growth 5YN/A
Sales Q2Q%18.1%

3.2 Future

Based on estimates for the next years, WAY will show a very strong growth in Earnings Per Share. The EPS will grow by 75.36% on average per year.
The Revenue is expected to grow by 9.90% on average over the next years. This is quite good.
EPS Next Y318.79%
EPS Next 2Y116.92%
EPS Next 3Y75.36%
EPS Next 5YN/A
Revenue Next Year8.5%
Revenue Next 2Y9.2%
Revenue Next 3Y9.9%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
WAY Yearly Revenue VS EstimatesWAY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M 1B
WAY Yearly EPS VS EstimatesWAY Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 0.5 1 1.5

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for WAY. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 30.45, the valuation of WAY can be described as expensive.
WAY's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. WAY is cheaper than 78.38% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 20.42. WAY is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 30.45
WAY Price Earnings VS Forward Price EarningsWAY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100 -150 -200 -250

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, WAY is valued a bit cheaper than 78.38% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, WAY is valued a bit cheaper than the industry average as 70.27% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 49.1
EV/EBITDA 25.94
WAY Per share dataWAY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
WAY's earnings are expected to grow with 75.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y116.92%
EPS Next 3Y75.36%

More info and screens

0

5. Dividend

5.1 Amount

WAY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

WAYSTAR HOLDING CORP

NASDAQ:WAY (5/7/2025, 1:23:48 PM)

40.44

+0.05 (+0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)04-30 2025-04-30/amc
Earnings (Next)N/A N/A
Inst Owners52.21%
Inst Owner Change2.64%
Ins Owners1.11%
Ins Owner Change5.05%
Market Cap7.00B
Analysts85
Price Target48.76 (20.57%)
Short Float %5.26%
Short Ratio1.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)66.95%
Min EPS beat(2)29.95%
Max EPS beat(2)103.96%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)5.18%
Min Revenue beat(2)4.13%
Max Revenue beat(2)6.23%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.05%
PT rev (3m)22.02%
EPS NQ rev (1m)0.22%
EPS NQ rev (3m)75.22%
EPS NY rev (1m)-0.1%
EPS NY rev (3m)57.58%
Revenue NQ rev (1m)-0.07%
Revenue NQ rev (3m)2.43%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 30.45
P/S 7.42
P/FCF 49.1
P/OCF 41.21
P/B 2.27
P/tB N/A
EV/EBITDA 25.94
EPS(TTM)-0.16
EYN/A
EPS(NY)1.33
Fwd EY3.28%
FCF(TTM)0.82
FCFY2.04%
OCF(TTM)0.98
OCFY2.43%
SpS5.45
BVpS17.8
TBVpS-5.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.42%
ROE -0.62%
ROCE 2.79%
ROIC 2.21%
ROICexc 2.3%
ROICexgc 51.39%
OM 13.11%
PM (TTM) N/A
GM 66.54%
FCFM 15.1%
ROA(3y)-0.88%
ROA(5y)N/A
ROE(3y)-1.85%
ROE(5y)N/A
ROIC(3y)2.09%
ROIC(5y)N/A
ROICexc(3y)2.13%
ROICexc(5y)N/A
ROICexgc(3y)47.51%
ROICexgc(5y)N/A
ROCE(3y)2.64%
ROCE(5y)N/A
ROICexcg growth 3Y7.56%
ROICexcg growth 5YN/A
ROICexc growth 3Y30.65%
ROICexc growth 5YN/A
OM growth 3Y7.95%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5YN/A
F-Score6
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF 8.73
Debt/EBITDA 3.97
Cap/Depr 14.61%
Cap/Sales 2.89%
Interest Coverage 250
Cash Conversion 54.7%
Profit Quality N/A
Current Ratio 2.55
Quick Ratio 2.55
Altman-Z 3.09
F-Score6
WACC10.69%
ROIC/WACC0.21
Cap/Depr(3y)12.11%
Cap/Depr(5y)N/A
Cap/Sales(3y)2.69%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%227.86%
EPS Next Y318.79%
EPS Next 2Y116.92%
EPS Next 3Y75.36%
EPS Next 5YN/A
Revenue 1Y (TTM)19.28%
Revenue growth 3Y17.71%
Revenue growth 5YN/A
Sales Q2Q%18.1%
Revenue Next Year8.5%
Revenue Next 2Y9.2%
Revenue Next 3Y9.9%
Revenue Next 5YN/A
EBIT growth 1Y-12.92%
EBIT growth 3Y27.06%
EBIT growth 5YN/A
EBIT Next Year123.38%
EBIT Next 3Y40.28%
EBIT Next 5YN/A
FCF growth 1Y375.9%
FCF growth 3Y15.76%
FCF growth 5YN/A
OCF growth 1Y229.9%
OCF growth 3Y16.85%
OCF growth 5YN/A